一个关于错误信息的曲折故事：伊维菌素是否应被批准用于治疗新冠疾病？
A twisting tale of misinformation: should ivermectin be approved as a treatment for COVID-19 disease?
作者信息
Shafiee Arman, Teymouri Athar Mohammad Mobin, Mozhgani Sayed-Hamidreza
机构信息
Clinical Research Development Unit, Alborz University of Medical Sciences, Karaj, Iran.
Student Research Committee, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.
出版信息
Future Virol. 2023 Feb. doi: 10.2217/fvl-2023-0006. Epub 2023 Mar 9.
Abstract
This editorial examines what has caused the evidence around ivermectin to be so controversial, provides a brief analysis of recently published evidence, and highlights why it is important to learn lessons from ivermectin for future re-purposed drugs.
摘要
这篇社论探讨了导致伊维菌素相关证据如此具有争议性的原因，简要分析了最近发表的证据，并强调了从伊维菌素中吸取教训对未来重新利用药物的重要性。
相似文献
1
A twisting tale of misinformation: should ivermectin be approved as a treatment for COVID-19 disease?一个关于错误信息的曲折故事：伊维菌素是否应被批准用于治疗新冠疾病？
Future Virol. 2023 Feb. doi: 10.2217/fvl-2023-0006. Epub 2023 Mar 9.
2
Social Media and COVID-19-Perceptions and Public Deceptions of Ivermectin, Colchicine and Hydroxychloroquine: Lessons for Future Pandemics.社交媒体与新冠疫情——关于伊维菌素、秋水仙碱和羟氯喹的认知与公众误导：对未来大流行的启示
Antibiotics (Basel). 2022 Mar 25;11(4):445. doi: 10.3390/antibiotics11040445.
3
Death from COVID-19 of a 57-year-old man refusing medical care and self-medicating with ivermectin.一名57岁男子因拒绝医疗护理并自行服用伊维菌素治疗新冠而死亡。
Cent Eur J Public Health. 2022 Dec;30(4):265-267. doi: 10.21101/cejph.a7643.
4
Ivermectin in COVID-19 Management: What is the Current Evidence?伊维菌素在 COVID-19 管理中的应用：目前有哪些证据？
Infect Disord Drug Targets. 2022;22(4):e190122200367. doi: 10.2174/1871526522666220119114035.
5
Changes in dispensing of medicines proposed for re-purposing in the first year of the COVID-19 pandemic in Australia.在 COVID-19 大流行的第一年，澳大利亚拟重新利用的药品配药变化。
PLoS One. 2022 Jun 15;17(6):e0269482. doi: 10.1371/journal.pone.0269482. eCollection 2022.
6
Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial.伊维菌素预防 COVID-19 患者住院（IVERCOR-COVID19）：一项随机、双盲、安慰剂对照试验。
BMC Infect Dis. 2021 Jul 2;21(1):635. doi: 10.1186/s12879-021-06348-5.
7
The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.SARS-CoV-2 依维莫司纳瓦拉-ISGlobal 试验（SAINT）评估依维莫司在症状出现后 48 小时内降低低危、非重症 COVID-19 患者 COVID-19 传播风险的潜力：一项随机对照试验方案的研究方案结构化总结。
Trials. 2020 Jun 8;21(1):498. doi: 10.1186/s13063-020-04421-z.
8
Role of ivermectin in patients hospitalized with COVID-19: a systematic review of literature.伊维菌素在 COVID-19 住院患者中的作用：文献系统评价。
Adv Respir Med. 2021;89(4):413-418. doi: 10.5603/ARM.a2021.0088.
9
The Effect of Ivermectin on Cases of COVID-19.伊维菌素对 COVID-19 病例的影响。
Cardiovasc Revasc Med. 2022 Nov;44:98-100. doi: 10.1016/j.carrev.2022.06.004. Epub 2022 Jun 17.
10
Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes.伊维菌素作为一种治疗 COVID-19 的潜在药物：临床与计算属性的同步评价。
Pharmacol Rep. 2021 Jun;73(3):736-749. doi: 10.1007/s43440-020-00195-y. Epub 2021 Jan 3.
引用本文的文献
1
Considering ivermectin for treatment of schistosomiasis.考虑用伊维菌素治疗血吸虫病。
Parasitol Res. 2024 Apr 9;123(4):180. doi: 10.1007/s00436-024-08178-1.
2
Cholesterol and COVID-19-therapeutic opportunities at the host/virus interface during cell entry.胆固醇与 COVID-19——细胞进入过程中宿主/病毒界面的治疗机会。
Life Sci Alliance. 2024 Feb 22;7(5). doi: 10.26508/lsa.202302453. Print 2024 May.
本文引用的文献
1
Ivermectin: A Controversial Focal Point during the COVID-19 Pandemic.伊维菌素：新冠疫情期间的一个争议焦点。
Life (Basel). 2022 Sep 6;12(9):1384. doi: 10.3390/life12091384.
2
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.二甲双胍、伊维菌素和氟伏沙明治疗 COVID-19 的随机试验。
N Engl J Med. 2022 Aug 18;387(7):599-610. doi: 10.1056/NEJMoa2201662.
3
Systematic review and meta-analysis of ivermectin for treatment of COVID-19: evidence beyond the hype.系统评价和荟萃分析伊维菌素治疗 COVID-19：超越炒作的证据。
BMC Infect Dis. 2022 Jul 23;22(1):639. doi: 10.1186/s12879-022-07589-8.
4
Using Twitter data to understand public perceptions of approved versus off-label use for COVID-19-related medications.利用 Twitter 数据了解公众对 COVID-19 相关药物的批准用途和标签外使用的看法。
J Am Med Inform Assoc. 2022 Sep 12;29(10):1668-1678. doi: 10.1093/jamia/ocac114.
5
Ivermectin under scrutiny: a systematic review and meta-analysis of efficacy and possible sources of controversies in COVID-19 patients.伊维菌素备受关注：COVID-19 患者疗效的系统评价和荟萃分析及可能引发争议的原因。
Virol J. 2022 Jun 13;19(1):102. doi: 10.1186/s12985-022-01829-8.
6
Meta-Analyses Do Not Establish Improved Mortality With Ivermectin Use in COVID-19.荟萃分析未证实使用伊维菌素治疗新冠肺炎可改善死亡率。
Am J Ther. 2022 Feb 10;29(2):e237-e244. doi: 10.1097/MJT.0000000000001477.
7
Can anti-parasitic drugs help control COVID-19?抗寄生虫药物能帮助控制新冠病毒吗？
Future Virol. 2022 Mar. doi: 10.2217/fvl-2021-0160. Epub 2022 Mar 18.
8
Ivermectin for the prevention of COVID-19: addressing potential bias and medical fraud.伊维菌素预防 COVID-19：应对潜在的偏见和医疗欺诈。
J Antimicrob Chemother. 2022 Apr 27;77(5):1413-1416. doi: 10.1093/jac/dkac052.
9
From hydroxychloroquine to ivermectin: how unproven "cures" can go viral.从羟氯喹到伊维菌素：未经证实的“疗法”是如何迅速传播的。
Clin Microbiol Infect. 2022 Apr;28(4):472-474. doi: 10.1016/j.cmi.2022.01.008. Epub 2022 Feb 3.
10
Safety cannot justify the use of ivermectin for the management of COVID-19.安全性不能成为使用伊维菌素治疗新冠肺炎的理由。
QJM. 2022 Mar 22;115(3):194-195. doi: 10.1093/qjmed/hcac019.
Zotero 插件